Positron Emission Tomography (PET) radiotracers in oncology – utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

Positron Emission Tomography (PET) radiotracers in oncology – utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC)

Published:2008-10-17 Issue:1 Volume:27 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Miele Evelina,Spinelli Gian Paolo,Tomao Federica,Zullo Angelo,De Marinis Filippo,Pasciuti Giulia,Rossi Luigi,Zoratto Federica,Tomao Silverio

Abstract

Abstract PET (Positron Emission Tomography) is a nuclear medicine imaging method, frequently used in oncology during the last years. It is a non-invasive technique that provides quantitative in vivo assessment of physiological and biological phenomena. PET has found its application in common practice for the management of various cancers. Lung cancer is the most common cause of death for cancer in western countries. This review focuses on radiotracers used for PET scan with particular attention to Non Small Cell Lung Cancer diagnosis, staging, response to treatment and follow-up

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1186/1756-9966-27-52.pdf

Reference98 articles.

1. Pantaleo MA, Nannini M, Maleddu A, et al: Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev. 2008, 34 (2): 103-21. 10.1016/j.ctrv.2007.10.001.

2. Smith TA: The rate-limiting step for tumor [18F]fluoro-2-deoxy-Dglucose (FDG) incorporation. Nucl Med Biol. 2001, 28 (1): 1-4. 10.1016/S0969-8051(00)00177-3.

3. Bourguet P, Blanc-Vincent MP, Boneu A, Bosquet L, et al: Summary of the standards options and recommendations for the use of Positron Emission Tomography with 2-[18F] Fluoro-2-deoxy-d-Glucose (FDG-PET scanning) in Oncology. BJC. 2003, 89: S84-S91.

4. Ung YC, Maziak DE, et al: 18Fluorodeoxyglucose Positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst. 2007, 99 (23): 1753-1767. 10.1093/jnci/djm232.

5. Son P, Atkins HE, et al: A fluorinate glucose analogue, 2-fluoro-2-deoxy-D-Glucose (F-18): nontoxic tracer for rapid tumour detection. J Nucl Med. 1980, 21: 670-675.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adversarial EM for variational deep learning: Application to semi-supervised image quality enhancement in low-dose PET and low-dose CT;Medical Image Analysis;2024-10

2. Response Evaluation Criteria in Gastrointestinal and Abdominal Cancers: Which to Use and How to Measure;RadioGraphics;2024-05-01

3. Motion-correction strategies for enhancing whole-body PET imaging;Frontiers in Nuclear Medicine;2024-02-07

4. Synthetic ¹⁸F labeled biomolecules that are selective and promising for PET imaging: major advances and applications;RSC Medicinal Chemistry;2024

5. Nanomaterial-Driven Advancements in Early Cancer Detection;Personalized and Precision Nanomedicine for Cancer Treatment;2024